ESR1 and neoplasm: Moreover, the xenograft model also showed that overexpressing SNHG17 countervailed the inhibitory effect of palbociclib plus fulvestrant treatment on tumor growth, besides, the increased LATS1 level and decreased ER-α level induced by palbociclib plus fulvestrant treatment in xenograft tumor tissues were also reversed by overexpression of LATS1.